MedTech intellectual property · Sophia Antipolis, France

Autonomous Mechanical Infusion Technology

PERFU+3 is a protected mechanical medical technology platform in pre-industrial maturation, designed for emergency, transport and constrained environments where dependence on batteries, electronics or embedded software may become an operational limitation.

100% mechanical No battery No electronics No embedded software
PERFU+3 mechanical infusion technology platform, closed configuration
PERFU+3 Current design rendering · non-contractual illustration
Mechanical by design Pressure generation and essential operating functions without external electrical power.
100% mechanical operating principle
3 French patent applications filed
CIR-V40 controlled development baseline
Pre-industrial maturation & transfer preparation

Why mechanical autonomy

Reducing technical dependency where conditions are demanding

PERFU+3 explores a deliberately simple approach to pressurised infusion: provide controlled mechanical compression of a flexible IV bag without requiring a battery, electronic control unit or embedded software.

The operational constraint

Power and electronic dependency can become a limitation

Transport, emergency and degraded environments can impose charging constraints, limited infrastructure, cold exposure, vibration, logistics burden and reduced maintenance capacity.

The PERFU+3 approach

Keep the essential function mechanical

The platform is developed around passive mechanical functions for actuation, guidance, pressure application and safety limiting, with the objective of delivering a robust and transferable medical technology architecture.

PERFU+3 mechanical infusion platform in open configuration, showing the mechanical assembly
Open configuration rendering. Illustration for first-level technical understanding only; detailed definition remains controlled.

PERFU+3 technology

A passive mechanical platform for controlled bag pressurisation

PERFU+3 is designed to apply controlled mechanical pressure to flexible infusion bags throughout use, without relying on electrical energy or software-driven control.

01

Mechanical pressure application

Spring energy and guided mechanical transmission are used to apply controlled compression to the infusion bag.

02

Passive safety architecture

Pressure limiting is developed as an independent mechanical function, without dependence on electronic sensing or software logic.

03

Human-factor oriented mechanics

Guiding, handling and anti-error features are integrated mechanically to support straightforward preparation and use.

04

Transfer-oriented engineering

The platform is supported by configuration-controlled technical documentation, engineering definitions, risk work and verification planning for future industrial transfer.

Potential environments of use

Designed for demanding medical contexts

The technological relevance of PERFU+3 is strongest where autonomy, simplicity and reduced dependency on electrical infrastructure are desirable.

01

Emergency & pre-hospital

Rapid-deployment contexts where power infrastructure may not be immediately available.

02

Medical transport

Ground and transport situations where compactness and reduced energy dependency are valuable.

03

Operational health

Potential relevance for tactical and military medical environments requiring robust, battery-free equipment.

04

Disaster response

Degraded or mass-casualty environments in which normal electrical infrastructure cannot be assumed.

05

Remote & austere care

Remote, maritime, mountain or other constrained environments with demanding logistics.

06

Civil protection

Resilience and continuity-of-care scenarios where equipment independence can support operational readiness.

Defence positioning: military and tactical applications are potential use cases to be evaluated with competent stakeholders. PERFU+3 is not presented as a military-qualified product.

Development status

A protected technology in pre-industrial maturation

PERFU+3 is not a commercial medical device. AXELYUM MEDTECH is continuing technical maturation, verification preparation and industrial-transfer structuring before partner-led industrialisation and regulatory execution.

IP

Protected platform

Three French patent applications filed. International extension strategy under evaluation.

Engineering

Controlled baseline

CIR-V40 is maintained as the current controlled development framework as the design matures.

Evidence

Structured dossier

Design definition, requirements, risk work and verification documentation are maintained under configuration control.

Transfer

Preparation underway

Industrial transfer documentation and partner-facing materials are being progressively consolidated.

AXELYUM MEDTECH

Develop, protect, mature and transfer mechanical medical technologies

AXELYUM MEDTECH is a French MedTech technology company focused on intellectual property, mechanical medical-device engineering and preparation for industrial transfer.

The company does not position itself as the future series manufacturer. Its model is to create and mature protected technology assets, then engage qualified industrial partners for industrialisation, regulatory execution, manufacturing and market access.

Legal name
AXELYUM MEDTECH SASU
SIREN / SIRET
105 779 011 · 105 779 011 00011
Activity
72.19Z — R&D in physical and natural sciences
Registered office
Les Aqueducs – Bâtiment 3, 535 Route des Lucioles, 06560 Valbonne, France
Founder
Luc Pichotte — Président & Fondateur
Business model
IP development · Licensing · Industrial transfer · Co-development

Industrial partnership

Built for qualified industrial dialogue

AXELYUM seeks partners able to assess the technology, contribute to its industrial maturation, execute the regulatory pathway and bring the resulting device to market.

AXELYUM MEDTECH contributes

  • Protected mechanical technology and patent portfolio
  • Controlled development baseline and technical architecture
  • Structured engineering and risk documentation
  • Know-how transfer and technical support
  • Flexible licensing or co-development framework

The industrial partner contributes

  • Design-for-manufacture and industrialisation capability
  • Series manufacturing and supplier qualification
  • Regulatory strategy and conformity assessment
  • Clinical / usability work where required
  • Distribution, market access and post-market organisation

Qualified enquiries

Discuss PERFU+3 with AXELYUM MEDTECH

For industrial transfer, licensing, co-development, strategic partnership or institutional discussions. Detailed technical information is shared selectively and, where appropriate, under NDA.

Luc Pichotte · Président & Fondateur AXELYUM MEDTECH SASU · Sophia Antipolis · France luc.pichotte@axelyumhealth.com

PERFU+3 is a protected technology platform under development. Please do not send confidential technical information before a suitable NDA is in place.

Open contact form